BioKier is an early-stage medical food and pharmaceutical company developing new proprietary oral products for people who are not able to manage their glucose.  The product was developed to mimic the mechanism through which metabolic bypass surgery has been proven to improve or resolve diabetes in the significant majority of patients that undergo the bypass surgery for obesity. BioKier’s oral product will potentially also help in managing hypertriglyceridemia, metabolic syndrome, and obesity.

BioKier, Inc. has created a network of partnerships with experts in pharmaceutical development, medical treatment, business strategy, law, and laboratory services. This allows BioKier to utilize specialized guidance and advice at every step of the development process.

Colonic delivery of nutrients for management of blood glucose in type 2 diabetes patients

BioKier has published an article summarizing our pre-clinical and clinical research: “Colonic delivery of nutrients for management of blood glucose in type 2 diabetes patients”.  The data validate BioKier’s approach to managing glucose using colon-targeted nutrients. This article was published in pear review journal: Functional Foods in Health and Disease. Below you will find link to the article: http://ffhdj.com/index.php/ffhd/article/view/283/574.
Read More

5th Annual World Congress of Food and Nutrition, Kaohsiung, Taiwan

Dr. George Szewczyk, presented at the 5th Annual World Congress of Food and Nutrition, held November 18-20, 2016, at The Conference Venue – Kaohsiung Exhibition Center in Kaohsiung, Taiwan.
Read More

Target Controlled Delivery of a Small Molecule to the Colon

Dr. Jennifer Law of Encap Drug Delivery, A Division of Capsugel, Livingston, West Lothian, Scotland, United Kingdom…
Read More